Novo’s Victoza left out of Express list once again
America’s largest pharmacy benefit manager, Express Scripts, is still opting for rival products over Novo Nordisk’s Victoza, while a new drug to treat obesity has also been cut from the list.
BY STEFAN SINGH KAILAY
Most observers had expected it to happen, but there might still be an air of disappointment in Bagsværd as Express Scripts once again left Novo Nordisk’s GLP-1 analogue Victoza out of its preferred drug list for 2016.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Nordisk silent about the loss of massive contract
For abonnenter
